Is It Time To Reconsider Bausch + Lomb (BLCO) After Recent Share Price Weakness [Yahoo! Finance]
Bausch + Lomb Corporation (BLCO)
Company Research
Source: Yahoo! Finance
If you are wondering whether Bausch + Lomb shares offer good value at today's price, it helps to first get clear on what the current market is actually pricing in. The stock last closed at US$16.20, with a 7 day return of a 5.0% decline, a 30 day return of a 4.9% decline, a year to date return of a 2.3% decline, and a 1 year return of 5.5%. Recent headlines around Bausch + Lomb have focused on its position in the eye care market and investor interest in its long term growth prospects. This mix of attention and shifting sentiment helps explain why the share price has moved over different time frames. On our simple 6 point valuation checklist, Bausch + Lomb scores 5 out of 6 for being assessed as undervalued. This sets up a closer look at how different valuation approaches line up and hints at an even more complete way to think about value that we will come back to at the end. Bausch + Lomb delivered 5.5% returns over the last year. See how this stacks up to the rest of the Med
Show less
Read more
Impact Snapshot
Event Time:
BLCO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
BLCO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
BLCO alerts
High impacting Bausch + Lomb Corporation news events
Weekly update
A roundup of the hottest topics
BLCO
News
- A Bausch + Lomb Director Just Bought $77,000 in Stock. That's Only Half the Story [Yahoo! Finance]Yahoo! Finance
- Bausch + Lomb Corporation (BLCO) Discusses Glaucoma Pipeline Focus With Updates on BL1107 and Elios Transcript [Seeking Alpha]Seeking Alpha
- Ophthalmic Diagnostic Devices Market Size to Hit USD 5.22 Billion by 2035 Due to Growing Demand for Early Eye Disease Detection – SNS Insider [Yahoo! Finance]Yahoo! Finance
- Bausch + Lomb Announces Positive 24-Month U.S. Data on the ELIOS™ System for Treatment of Glaucoma [Yahoo! Finance]Yahoo! Finance
- Bausch + Lomb Announces Positive 24-Month U.S. Data on the ELIOS™ System for Treatment of GlaucomaBusiness Wire
BLCO
Earnings
- 2/18/26 - Miss
BLCO
Sec Filings
- 3/10/26 - Form 4
- 3/10/26 - Form 4
- 3/10/26 - Form 4
- BLCO's page on the SEC website